Plus Therapeutics | 10-Q: Q3 2024 Earnings Report
Plus Therapeutics | 424B3: Prospectus
Plus Therapeutics | 8-K: Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Plus Therapeutics | 424B3: Prospectus
Plus Therapeutics | 8-K: Current report
Plus Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Hawkins Richard J
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Petersen Greg
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Clowes Howard
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sims Andrew John Hugh MacIntyre
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Clowes Howard
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Lenk Robert P
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HEDRICK MARC H
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer HEDRICK MARC H
Plus Therapeutics | 424B3: Prospectus
Plus Therapeutics | 8-K: Current report
Plus Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Plus Therapeutics | 424B3: Prospectus
Plus Therapeutics | 8-K: Current report
No Data